Search Results
Your search for ,HIS matches 4421 pages
Showing 51 - 100Cancer Has Plagued My Family
My twin brother and I were adopted at 18 months old, so I don’t know the medical history of our biological parents and family. But for certain, cancer has played an integral—and heartbreaking—role in my life. Both of my adoptive parents were diagnosed with genitourinary cancers at relatively early ...
ASH to Present 2024 Honorific Awards at Annual Meeting
The American Society of Hematology (ASH) will recognize exemplary hematologists who have made significant contributions to the field with several honorific awards at the 2024 ASH Annual Meeting and Exposition, being held December 7–10 in San Diego. “ASH is honored to recognize these outstanding...
New Technique May Allow for Visualization of CAR T Cells Postinjection
The University of Cincinnati Cancer Center announced the launch of a new study funded by a $2.3 million National Cancer Institute (NCI) grant to develop a novel technique to visualize where genetically modified immune cells go after being administered in patients with cancer. Background During...
A Diagnosis of Lymphoma Has Changed My Life
I’m 50, just a year older than my father was when he died of colorectal cancer. I was 14 when my dad died, so to me, cancer has always been synonymous with death. From a young age, my brothers and I had a goal: to make sure we packed in enough life before age 50. It never occurred to us that death ...
William Gradishar, MD, on Advances in Endocrine Therapeutic Options for Patients With ER-Positive, HER2-Negative Breast Cancer
William Gradishar, MD, discusses advances in endocrine therapeutic options for patients with estrogen receptor–positive, HER2-negative breast cancer, in follow-up to his presentation at the Lynn Sage Breast Cancer Symposium, October 2024. Dr. Gradishar is the Betsy Bramsen Professor of Breast...
Case Study Shows Striking Improvements in Patient Treated for Metastatic Prostate Cancer With Antibody-Drug Conjugate
A landmark case report suggested a potential breakthrough in the treatment of an aggressive type of prostate cancer, according to a recent study published by Lap et al in the Annals of Internal Medicine. The antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) was approved by the U.S....
Sunil S. Badve, MD, FRCPath, on Tumor-Infiltrating Lymphocytes in the Patient With Breast Cancer
Sunil S. Badve, MD, FRCPath, discusses research on tumor-infiltrating lymphocytes in the patient with breast cancer, based in part on his presentation at the Lynn Sage Breast Cancer Symposium, October 2024. Dr. Badve is Professor, Department of Pathology and Laboratory Medicine, and Vice Chair,...
Charles E. Geyer, Jr, MD, FACP, on Management of the Patient With HER2-Positive Breast Cancer in 2024
Charles E. Geyer, Jr, MD, FACP, discusses the management of patients with HER2-positive breast cancer in 2024, based in part on his presentation at the Lynn Sage Breast Cancer Symposium, October 2024. Dr. Geyer is Professor of Medicine and Interim Division Chief of Malignant Hematology and Medical...
Frederick Howard, MD, on the Role of Targeted Therapy and Endocrine Therapy in the Patient With Breast Cancer
Frederick Howard, MD, discusses the role of targeted therapy and endocrine therapy in the patient with breast cancer, based in part on his presentation at the Lynn Sage Breast Cancer Symposium, October 2024. Dr. Howard is Assistant Professor of Medicine in the section of Hematology/Oncology at the...
National Academy of Medicine Elects 100 New Members
The National Academy of Medicine (NAM) announced the election of 90 regular members and 10 international members during its annual meeting. Background Established originally as the Institute of Medicine in 1970 by the National Academy of Sciences, NAM addresses critical issues in health, science,...
Meeting the Long-Term Challenge of Achieving Equity in Global Cancer Care
Although significant progress has been made against cancer, especially in the United States, which has seen the overall death rate from cancer fall by 33% over the past 3 decades, translating into averting an estimated 3.8 million deaths from the disease,1 progress worldwide has not been as...
Shared Reflections on the 2024 ASCO Annual Meeting: From Networking to Mentorship and More, Part 2
In the October 10, 2024, issue of The ASCO Post, we shared some unique insights from several recipients of the international development and education award (IDEA). As oncologists and cancer researchers from diverse low- and middle-income countries, their experiences at the 2024 ASCO Annual Meeting ...
Three Days Was Enough
My dad agreed to receive hospice on a technicality. It happened after weeks of trying to get him home oxygen. My brother drove him to the oncologist’s office, and I helped him get into the wheelchair. He did not complain, but just asked me to hold his coffee mug, smiling because I snuck him a...
Advancing Diversity, Equity, and Inclusion Through a Challenging Policy Landscape
Among most members of the health-care and oncology workforces, the lofty goals of the organizational framework of diversity, equity, and inclusion (DEI) seem to be clear and indisputable: to promote the fair treatment and full participation of all people, particularly groups who have historically...
Trial Updates in Stage III Melanoma Solidify the Neoadjuvant Use of Immunotherapy as the Current Standard of Care
Neoadjuvant therapy for patients with resectable stage III melanoma has recently emerged as a better approach than resection plus adjuvant therapy. At the European Society for Medical Oncology (ESMO) Congress 2024, updates of pivotal neoadjuvant studies demonstrated the long-standing benefit of...
Can Blood Test Predict Survival in Metastatic Prostate Cancer?
A recent study found that measuring circulating tumor cells (CTCs) is a reliable way to predict later treatment response and survival prospects in men when metastatic prostate cancer is first diagnosed. The test may help providers to decide which patients should receive standard treatment vs who...
Shared Reflections on the 2024 ASCO Annual Meeting: From Networking to Mentorship and More
The ASCO Annual Meeting brings together oncologists, researchers, and health-care professionals to share the latest advancements in cancer care. The 2024 ASCO Annual Meeting (ASCO24) was particularly momentous for those of who received the international development and education award (IDEA). As...
Two U.S. Scientists Named Recipients of the 2024 Nobel Prize in Physiology or Medicine
The 2024 Nobel Prize in Physiology or Medicine has been awarded jointly to two U.S. scientists: Victor Ambros, PhD, and Gary Ruvkun, PhD, for the discovery of microRNA and its role in post-transcriptional gene regulation. The recipients were named in a news release issued by The Nobel Assembly at ...
Distinguished Service Awards Presented at the IASLC World Conference on Lung Cancer
Distinguished Service Awards were presented to Kwun Fong, MBBS, PhD, FRACP; Claudia Henschke, MD, PhD; Erik Thunnissen, MD, PhD; and Julie Brahmer, MD, MSc, FASCO, during the 2024 International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer. Adi F. Gazdar IASLC...
KEYNOTE-A18: Overall Survival in Cervical Cancer Improved by Pembrolizumab Plus Chemoradiotherapy
In the phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 trial presented at the European Society for Medical Oncology (ESMO) Congress 2024, the PD-1 inhibitor pembrolizumab plus chemoradiotherapy, with pembrolizumab continued as monotherapy, improved overall survival in previously untreated, high-risk...
A Clinical Trial Has Halted Progression of Merkel Cell Carcinoma and Allowed Me to Pursue My Love of Music
At the age of 75, I’m just happy to still be here and be able to continue to contribute to my musical community. When I was diagnosed with Merkel cell carcinoma in 2021, I had never heard of the cancer and didn’t realize how aggressive and deadly it is. It was especially surprising to get such a...
ASCO Presents Ethan Basch, MD, MSc, FASCO, With the Joseph Simone Quality Care Award
ASCO will recognize Ethan Basch, MD, MSc, FASCO, a medical oncologist and Distinguished Professor at the University of North Carolina, with the Joseph Simone Quality Care Award and Lecture at the 2024 ASCO Quality Care Symposium. This year’s meeting will be held in San Francisco and online on...
The Formative Years of Medical Oncology in the United States: A Rough and Tumble Road, Part 2
Medical oncology had a turbulent beginning, as we explained in part 1 of this commentary published in the September 25, 2024, issue of The ASCO Post. And although no other specialty we know of struggled as much, with perseverance and time, it had become a stable specialty of internal medicine by...
The Formative Years of Medical Oncology in the United States: A Rough and Tumble Road, Part 1
Medical oncology had a turbulent beginning. No other specialty we know of struggled as much. But by 1980, it had become a stable specialty of internal medicine and was off and running—with the major problem of how to marshal available resources to freely test the myriad opportunities presented by ...
Artificial Intelligence Method Transforms Gene Mutation Prediction in Lung Cancer
Research suggests an artificial intelligence (AI) tool called DeepGEM may provide an advancement in genomic testing that offers an accurate, cost-effective, and timely method for gene mutation prediction from histopathology slides. The research was presented at the International Association for the ...
Too Much, Too Little, Just Right: Optimizing Cancer Care for Older Adults
Imagine walking into a fancy restaurant only to find a menu consisting mostly of kids’ dishes. It would make no sense. Just 25% of restaurant diners are younger than age 12, and they rarely write Yelp reviews. But when it comes to cancer treatment, this is not very far from what we do. The median...
T-DXd Effective for Breast Tumors With HER2-Low and HER2-Ultralow Expression in Earlier Line of Therapy
In patients with hormone receptor–positive metastatic breast cancers with HER2-low or HER2-ultralow expression, treatment with the antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) was found to be superior to chemotherapy after one or more lines of endocrine therapy. In...
Remembering a Pioneer in Melanoma and Immunotherapy: Jeffrey S. Weber, MD, PhD, FASCO
Jeffrey S. Weber, MD, PhD, FASCO, an internationally recognized pioneer in melanoma and cancer immunotherapy, died on August 19, 2024, according to an announcement from the Melanoma Research Foundation. He most recently served as Deputy Director of the Laura and Isaac Perlmutter Cancer Center at...
LIBRETTO-431 Trial Shows Selpercatinib Is Effective in East Asian Patients With RET Fusion–Positive Non–Small Cell Lung Cancer
A subgroup analysis of data from the LIBRETTO-431 trial (ClinicalTrials.gov identifier NCT04194944) showed that the selective RET inhibitor selpercatinib safely improved progression-free survival compared to chemotherapy plus pembrolizumab in East Asian patients diagnosed with RET fusion–positive...
Detecting Residual Disease After Neoadjuvant Chemoradiation in Esophageal Squamous Cell Carcinoma
Although esophageal cancer in the United States is relatively rare, affecting about 22,400 people each year and making up about 1% of all cancer cases,1 the disease is common in East and Central Asia countries. Nearly 90% of patients with esophageal cancer in Asia are diagnosed with the squamous...
Gift of Truth: Reflections on a Father’s Cancer Journey
It was a hot and humid Tuesday in July, and I distinctly remember being grateful for the air conditioning in the pastel-shaded waiting room of the oncology outpatient clinic. My father sat silently beside me. We knew this room well, as we did the doctor we had arrived to see. He had been my...
Age Is Just a Number: Treatment Considerations for Endometrial Cancer in Older Women
Endometrial cancer is most frequently diagnosed among women aged 55 to 65, with a median age at diagnosis of 64 years.1 In epidemiologic studies, women diagnosed with endometrial cancer at an older age are more likely to have high-grade disease, aggressive histology, deep myometrial invasion, lower ...
Should Low-Dose CT Screening Be Recommended for Those at Low Risk for Lung Cancer?
Lung cancer remains the leading cause of cancer-related deaths worldwide. Detecting this disease in its early stages significantly improves survival rates, making low-dose computed tomography (CT) screening an essential component in the fight against lung cancer. Recent studies, particularly from...
Extranodal Marginal Zone Lymphoma: Is Overtreatment Common?
Most patients with extranodal marginal zone lymphoma (MZL) are overtreated, according to Emanuele Zucca, MD, of the Oncology Institute of Southern Switzerland and Institute of Oncology Research in Bellinzona and the Università della Svizzera Italiana in Lugano. “Aggressive therapy is not needed in...
In Remembrance of My Friend, Lyn Denny, MD, PhD: I Will Never Forget Her
I first met Lyn Denny, MD, PhD, in Ghana, in 2004, when she became the Secretary Treasurer of AORTIC and brought the organization back to life. We’ve been friends ever since. I equate Lyn’s unwavering dedication to bringing health equity to women in Africa to Nelson Mandela’s fight for social...
Cancer Research and Care Beyond Borders for Global Oncologist Dario Trapani, MD
In this installment of The ASCO Post’s Living a Full Life series, I interviewed Dario Trapani, MD, a medical oncologist at the European Institute of Oncology, Milan and Assistant Professor at the Department of Oncology and Haemato-Oncology of the University of Milan, in Italy. Dr. Trapani is a...
Localized Hepatocellular Carcinoma
This is Part 3 of Immunotherapy Strategies for Hepatobiliary Cancers, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Rachna T. Shroff, Nilo Azad, and Anthony B. El-Khoueiry discuss the management of localized hepatocellular...
Advanced Unresectable Hepatocellular Carcinoma
This is Part 1 of Immunotherapy Strategies for Hepatobiliary Cancers, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Rachna T. Shroff, Nilo Azad, and Anthony B. El-Khoueiry discuss the management of advanced unresectable...
Cancer and Fatherhood: A Story of Personal Power in the Face of a Mortal Disease
Iron Dad: A Cancer Survivor’s Story of Discovering Strength, Life, and Love Through Fatherhood by Paul Weigel is an inspiring and deeply moving memoir that transcends the traditional boundaries of parenthood and personal transformation. This story begins with a sense of discontent and a desire for...
Two Phase III Trials Report Benefit With Isatuximab-Based Regimens in Newly Diagnosed Multiple Myeloma
In newly diagnosed, transplant-ineligible patients with multiple myeloma, treatment with the anti-CD38 monoclonal antibody isatuximab plus bortezomib, lenalidomide, and dexamethasone (VRd) led to a 40% reduction in the risk of disease progression or death and “deep and sustained responses,” almost...
Joseph A. Sparano, MD, FACP, on Premenopausal HR-positive Early Breast Cancer: What to Do Outside the OFSET Trial?
Joseph A. Sparano, MD, FACP, of Icahn School of Medicine at Mount Sinai, discusses his presentation on premenopausal patients with hormone receptor–positive early breast cancer. Dr. Sparano is the Ezra M. Greenspan, MD, Professor in Clinical Cancer Therapeutics, Chief of the Division of Hematology...
Paolo Tarantino, MD, on the Current and Future Landscape of Antibody-Drug Conjugates
Paolo Tarantino, MD, of Dana-Farber Cancer Institute and Harvard Medical School, shares key points from his discussion on the current and future landscape of antibody-drug conjugates. Dr. Tarantino is an Advanced Research Fellow in the Breast Oncology Program at Dana-Farber Cancer Institute and...
Aditya Bardia, MD, MPH, FASCO, on Novel Therapies Targeting the Estrogen Receptor
Aditya Bardia, MD, MPH, FASCO, of UCLA Health/Jonsson Comprehensive Cancer Center, shares key points from his discussion on novel therapies targeting the estrogen receptor. Dr. Bardia is Professor, Department of Medicine, Division of Hematology/Oncology, and Director of Translational Research...
Aditya Bardia, MD, MPH, FASCO, on the Current and Future Landscape of Antibody-Drug Conjugates
Aditya Bardia, MD, MPH, FASCO, of UCLA Health/Jonsson Comprehensive Cancer Center, shares key points from his discussion on the current and future landscape of antibody-drug conjugates. Dr. Bardia is Professor, Department of Medicine, Division of Hematology/Oncology, and Director of Translational...
Neha Vapiwala, MD, FACR, FASTRO, FASCO, Voted President-Elect of ASTRO
The members of the American Society for Radiation Oncology (ASTRO) recently elected five new officers to ASTRO’s Board of Directors: Neha Vapiwala, MD, FACR, FASTRO, FASCO, President-Elect Jean Wright, MD, FASTRO, Clinical Affairs and Quality Council Vice Chair Andrea Ng, MD, MPH, FASTRO,...
Second-Line ALK-Positive NSCLC With CNS Progression on First-Line Crizotinib
This is Part 3 of ALK-Positive Metastatic NSCLC: Where Are We Now?, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Todd Bauer, Narjust Florez, and Sai-Hong Ignatius Ou discuss the second-line treatment of ALK-positive...
First-Line ALK-Positive NSCLC With CNS Metastases at Baseline and CNS Toxicity
This is Part 2 of ALK-Positive Metastatic NSCLC: Where Are We Now?, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Todd Bauer, Narjust Florez, and Sai-Hong Ignatius Ou discuss the first-line management of ALK-positive...
Having Acute Lymphoblastic Leukemia Took Away My Fear of Death
On May 30, 2017, 9 days before I turned 19 and soon after I had completed my sophomore year at college, I was diagnosed with aggressive acute lymphoblastic leukemia. But getting to the diagnosis was a tortuous process. I had been feeling fatigued and losing weight for several weeks prior to the...
ASCO to Present Ethan Basch, MD, MSc, FASCO, With the Joseph Simone Quality Care Award
ASCO will recognize Ethan Basch, MD, MSc, FASCO, a medical oncologist and Distinguished Professor at the University of North Carolina, with the Joseph Simone Quality Care Award and Lecture at the 2024 ASCO Quality Care Symposium. This year’s meeting will be held in San Francisco and online on...
Accelerating Progress in Melanoma and Cancer Research
The Melanoma Research Alliance is on a mission to cure and prevent melanoma, a skin cancer that is diagnosed in more than 100,000 people each year and is expected to take the lives of more than 8,000 individuals in 2024.1 We invite stakeholders across all fields, including medicine, science, and...
